SG Americas Securities’s Protalix BioTherapeutics PLX Stock Holding History

SG Americas Securities’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,155	Closed	-$31K	–	3589
2025 Q4	$31K	Buy	+17,155	New	+$35.1K	﹤0.01%	3421
2024 Q2	–	Sell	-21,467	Closed	-$27K	–	3210
2024 Q1	$27K	Sell	21,467 -13,139	-38%	-$19.6K	﹤0.01%	2842
2023 Q4	$62K	Buy	34,606 +4,598	+15%	+$7.15K	﹤0.01%	2886
2023 Q3	$50K	Buy	+30,008	New	+$53.9K	﹤0.01%	2942
2020 Q2	–	Sell	-22,500	Closed	-$53K	–	3813
2020 Q1	$53K	Hold	22,500	–	–	﹤0.01%	3163
2019 Q4	$74K	Hold	22,500	–	–	﹤0.01%	3011
2019 Q3	$46K	Hold	22,500	–	–	﹤0.01%	2825
2019 Q2	$106K	Sell	22,500 -16	-0.1%	-$68	﹤0.01%	2778
2019 Q1	$99K	Buy	22,516 +16	+0.1%	+$72	﹤0.01%	3078
2018 Q4	$70K	Hold	22,500	–	–	﹤0.01%	2784
2018 Q3	$164K	Hold	22,500	–	–	﹤0.01%	2658
2018 Q2	$97K	Hold	22,500	–	–	﹤0.01%	3089
2018 Q1	$121K	Buy	+22,500	New	+$148K	﹤0.01%	2802

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

SG Americas Securities's PLX Position: Q1 2026 in Review

SG Americas Securities sold out of Protalix BioTherapeutics (PLX) in Q1 2026, closing a stake of 17,155 shares — an estimated $31K sold.

SG Americas Securities first reported a position in PLX in Q1 2018 and held it in 13 quarters. The position peaked at $164K in Q3 2018. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

SG Americas Securities reported no remaining Protalix BioTherapeutics position as of Q1 2026 after selling out during the quarter.
SG Americas Securities sold 17,155 Protalix BioTherapeutics shares in Q1 2026, an estimated $31K.
SG Americas Securities first reported a position in Protalix BioTherapeutics in Q1 2018 and held it in 13 quarters.
SG Americas Securities's Protalix BioTherapeutics position peaked at $164K in Q3 2018.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.